FREE CME/CNE/CPE for FDA Webinar: Diversity in Clinical Trials: Learn about Enrollment Trends and Resources from FDA
Diversity in Clinical Trials: Learn about Enrollment Trends and Resources from FDA
December 16, 2020 | 1:00 - 2:30 p.m. Eastern
This webinar has been approved for 1.5 continuing medical, pharmacy, and nursing education units and is FREE. Please see detailed announcement for more details.
FDA guidance that supports diverse participation in clinical trials
Status of trial diversity after 5 years of Drug Trials Snapshots reporting
FDA's efforts that support clinical trial diversity
FDA will share CDER's most recent assessment of clinical trial diversity and discuss efforts to advance diverse participation in clinical trials to include relevant FDA guidance and regulations.
In this era of globalization, meeting various regulatory authorities' expectations in recruitment of diverse trial population is challenging. The need for faster drug development and shorter recruitment timelines make this important part of drug development even harder. CDER has pooled and analyzed 5-year's worth of demographic data from NME and original BLA approvals presented in Drug Trials Snapshot 2015-2019. In addition to sharing the observations and trends from trials of over 290,000 participants, the webinar will provide FDAs expectations when it comes to representation in the trials and various initiatives that were developed to help industry, recruitment sites and the public in general achieving these expectations.
AUDIENCE
Regulatory affairs professionals working on IND annual reports and NDA/BLA submissions
Researchers working on trial demographics and health equity
Foreign regulators
Clinical research coordinators and recruiters
Health policy and management experts interested in clinical trial participation
CONTINUING EDUCATION
Real-time attendance is required for the certificate of attendance. Certificates are only available during the three weeks post-event. This course:
has been approved for 1.5 continuing medical, pharmacy, and nursing credit. Please see detailed announcement for more details.
has been pre-approved by RAPS as eligible for up to 1.5 credits towards a participant's RAC recertification upon full completion.
has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
has been pre-approved by SQA as eligible for 0.25 non-GCP or non-GLP units for every 1 hour of instructional time towards a participant's RQAP re-registration.
has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.
The Small Business and Industry Assistance program in the Center for Drug Evaluation and Research (CDER SBIA) provides guidance, education and regular updates for regulated industry.
This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, please contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.
This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA
No comments:
Post a Comment